• Journal of Microbiology and Biotechnology
• /
• 제10권3호
• /
• pp.399-404
• /
• 2000

The adjuvant effect of a muramyl dipeptide (MDP) derivative, MDP-Lys(L18), on enhancing of antitumor immunity induced by X-irradiated tumor cells against highly metastatic B16-BL6 melanoma cells was examined in mice. Mice immunized intradermally (i.d.) with a mixture of X-irradiated B16-BL6 cells and MDP-Lys (L18) [Vac+MDP-Lys (L18)] followed by an intravenous (i.v.)inoculation of $10^4$ viable tumor cells 7 days after immunization, showed a significant inhibition of experimental lung metastasis of B16-BL6 melanoma cells. The most effective immunization for the prophylactic inhibition of tumor metastasis was obtained from the mixture of $100{\;}\mu\textrm{g}$ of MDP-Lys (L18) and $10^4$ X-irradiatied tumor vaccine. Furthermore, immunization of mice with Vac+MDP-Lys(L18), 3 days after tumor challenge, resulted in a significant inhibition of lung metastasis of B16-BL6 melanoma cells in an experimental lung metastasis model. Similarly, the administration of Vac+MDP-Lys(L18), 1 or 7 days after tumor removal, markedly inhibited tumor metastasis of B16-BL6 in a spontaneous lung metastasis model. When Vac+MDP-Lys (L18) was i.d. administered 3 days after subcutaneous (s.c.) inoculation of tumor cells ($5{\times}10^5/site$) on the back, mice treated with Vac+MDP-Lys(L18) showed inhibition of significantly tumor growth on day 20. These results suggest that MDP-Lys (L18) is able to enhance antitumor activity induced by X-irradiated tumor vaccine to reduce lung metastasis of tumor cells, and is a potent immunomodulating agent which may be applied prophylactically as well as therapeutically to treatment of cancer metastasis.

• Toxicological Research
• /
• 제28권4호
• /
• pp.225-233
• /
• 2012

The present study was carried out to examine the toxicity and target organs of oral cholera vaccine (OCV) after repeated oral administration in Sprague-Dawley rats for 6 weeks (3 administrations, once every 2 weeks). OCV is an inactivated oral cholera vaccine that contains Vibrio cholerae and confers protection against cholera caused by V. cholera serogroups O1 (Inaba and Ogawa serotypes) and O139 (strain 4260B). The animals were orally administered either OCV placebo (negative control) or OCV at a dose equivalent to 240 times the anticipated human dose. Throughout the administration period, no significant change was detected in clinical signs, body weight, food or water consumption, urinalysis results, hematological and clinical biochemistry test results, organ weights, necropsy, or histopathological examination results. Minor changes were found in hematological and clinical biochemistry tests; however, these changes were within normal ranges. The above results suggest that oral administration of OCV in rats did not induce any toxicologically meaningful changes, and the target organs could not be determined. This study was conducted in accordance with the guidelines established by Good Laboratory Practice (2009-183, KFDA, December 22, 2009) and the OECD Principles of Good Laboratory Practice (1997).

• Pediatric Infection and Vaccine
• /
• 제8권2호
• /
• pp.150-159
• /
• 2001

목 적 : 현재 사용하고 있는 마우스 뇌조직 유래 Nakayama주 사백신 접종 방법의 의학적 타당성을 알아보고자 접종 실태와 부작용 발생 양상과 빈도를 조사하고 추가 접종 방법의 타당성을 확인하기 위하여 중화항체 지속률을 조사하였다. 방 법 : 15,487명의 접종아를 대상으로 이상반응 발생 여부를 조사하였고 초등학교 학생 2,277명을 대상으로 건강기록부와 설문지조사를 통하여 접종실태와 이상반응 발생 빈도를 확인하였으며 접종기록이 일치하는 311명의 학생을 대상으로 중화항체 검사를 시행하였다. 검사는 United States Armed Forces Research Institute of Medical Science/Department of Virology, Bangkok(USAMC-AFRIMS)에서 시행되었고 50% 플라크 감소를 기준으로 1 : 10 이상을 양성으로 하였다. 결 과 : 건강기록부에 의한 초등학생 2,277명의 접종률은 47.5%였으나 설문지 조사에서는 접종률이 93.5%로 큰 차이가 있었다. 건강기록부에 나타난 취학 전 접종률은 남자 48.5%, 여자 46.4%로 차이가 없었다. 연령이 증가함에 따라 일본뇌염의 접종 횟수도 증가하는 양상을 보였다. 예방접종 여부가 건강기록부와 설문지 조사 결과가 일치하는 경우는 95년과 96년에 모두 접종 받았다고 응답한 경우만 75.6%로 높았고 그 외에는 일치도가 낮았다. 일본뇌염 예방접종 장소는 학교가 60.1%로 가장 많았고 그 외 보건소가 25.1%, 병 의원 14.1% 순이었다. 1995년 5~6월 사이 서울 소재 보건소에서 15,487명을 대상으로 일본뇌염 사백신을 접종한 후 0.13%에서 이상반응이 발생하여 의료 기관을 방문하였으며 이 중 57%는 고열 때문이었고 1례에서 접종 후 3분만에 실신 발작이 있었다. 전체 접종자의 0.02%에서 심한 두드러기 반응으로 의료기관을 방문하였으며 0.03%에서 두통 및 구토 등으로 의료 기관을 다시 찾았다. 1996년 봄에 초등학생을 대상으로 시행한 이상반응 설문지 조사에 의하면 주사 부위 발적이 17.4%, 주사 부위 동통이 14.8%, 발열 4.3%였고 그 외에 두통, 구토, 반점 등이 관찰되었다. 초등학생 311명 중 일본뇌염 접종력 조사에서 마지막 접종 후 6개월이 경과한 경우(1군)가 155명, 접종 후 18개월이 경과한 경우(2군) 104명, 30개월이 경과한 경우(3군)이 45명, 42개월이 경과한 경우(4군)가 7명이었다. 이들의 항체 양성률은 1군이 98.1%(152/155), 2군이 99.0%(103/104), 3군이 95.6%(43/45), 4군이 71.4%(5/7)로 양성률에 있어서 각 군간의 차이는 없는 것으로 나타났다. 결 론 : 현재 격년으로 시행하고있는 일본뇌염 사백신 추가 접종은 시기를 늘려 시행하여도 항체 지속률을 유지할 수 있을 것으로 추정된다.

• 대한수의학회지
• /
• 제47권3호
• /
• pp.291-298
• /
• 2007

Olive flounder, Paralichthys olivaceus is one of the most important cultured fish in Korea, its farming has been negatively impacted by viral, bacterial and parasitic diseases. Streptococcal infection was considered as a serious problem because of significant economic losses in olive flounder farm industry. The development and evaluation of vaccine for protection against infection by this agent were required. We evaluated the safety and efficacy of ${\beta}$-hemolytic Streptococcus (S.) iniae vaccine on olive flounder Three hundreds of flounders (weight $119.8{\pm}20.7g$, body length $22.6{\pm}1.4cm$) were reared in 0.5 tons aquaria in land-marine tank system. Seawater was provided from the sea of Inchon in Korea, and water temperature was set to $22^{\circ}C$ and $25^{\circ}C$ in the vaccination and challenge test, respectively. We used the formalin-inactivated ${\beta}$-hemolytic S. iniae (F2K) vaccine (M VAC INIAE; Kyoritsu seiyaku, Japan) originated in Japan. The vaccine was intraperitoneally administered to fish. Both of vaccinated group and control group were challenged with intraperitoneally injection by virulent S. iniae SI-36 isolates with $1.0{\times}10^7CFU/fish$ at 3 weeks after vaccination. Difference on mortality of control and vaccinated group (90.0 and 15.0%, 76.5 and 8.0% respectively) at two trials were found significant (p<0.05), and relative percent survival were 83.4% and 89.5%, respectively. The dead fishes were showed dark pigmentation of skin, abdominal extension, hemorrhagic ascites, and liver necrosis, and isolated the S. iniae strain from ascites, liver and kidney. We confirmed the safety and efficacy of ${\beta}$-hemolytic S. iniae vaccine by determinations of the optimal management condition and artificial challenge test in olive flounder.

• 미생물학회지
• /
• 제35권1호
• /
• pp.82-88
• /
• 1999

베로 세포에 적응시켜 개발된 약독화 일본뇌염 바이러스인 CJ5003 주를 이용해 제조된 새로운 2세대 일본뇌염 백신의 효과를 마우스에서 조사하였다. Adjuvant 로 aluminiu hydroxide gel을 사용한 경우, 그렇지 않은 경우에 비해 높은 일본뇌염 바이러스 특이 항체 유도능과 10배 향상된 중화항체 유도능을 보였으며, 항원의 양을 변화시켜 면역시킨 결과 0.5 ng 의 적은 항원양으로도 항체가 유발되었고 방어 가능한 수준인 1:10 이상의 중화항체가 유지되었다. 500ng의 항원양으로 면역된 마우스를 면역 초기부터 24주간 관찰한 결과 중화항체가가 14주까지 1:200 이상으로 계속 유지되었으며 24주에도 1:160을 유지하여 일본뇌염에 대한 방어효력이 장기간 유지되고 있음을 나타냈다. 또한 면역된 마우스 혈청은 Nakayama-NIH, SA14, P3 등 3종의 신경독성 일본뇌염 바이러스주에 대해서 각각 유사한 수준의 일본뇌염 바이러스 특이 항체가를 보여주어 다양한 일본뇌염 바이러스 주에 대한 방어 가능성을 보여주었다. 마우스를 이용한 뇌내 직접 공격 시험결과, CJ5003 후보 백신은 90% 이상의 높은 생존율을 나타냈다. 이상의 in vitro, in vivo 시험 결과는 베로 세포에서 생산된 CJ5003 후보 백신의 차세대 백신으로 개발 가능성을 시사한다.

• 한국임상수의학회지
• /
• 제26권3호
• /
• pp.226-230
• /
• 2009

We evaluated the efficacy of $\beta$-hemolytic Streptococcus(S.) iniae vaccine on cultured olive flounder. Three hundred flounders(weight $50{\pm}5$ g) were obtained from two farm at Wando and Taean in the southern and western coast of Korea at May and June 2007, respectively. Twenty of flounders moved in 0.5 tons aquaria in land-marine tank system of National Veterinary Research and Quarantine Service. Seawater was transported from the sea of Inchon in western Korea, and water temperature maintained to $22^{\circ}C$ and $25^{\circ}C$ during the vaccination and challenge test, respectively. We used the formalin-inactivated $\beta$-hemolytic S. iniae vaccine produced by domestic manufacturers. The vaccine was intraperitoneally administered to fish. The vaccinated and control group were challenged with intraperitoneal injection by virulent S. iniae SI-36 isolates with $5.0{\times}10^8$ CFU/fish at 3 weeks after vaccination. We evaluated the vaccine efficacy by calculating numbers of dead fish, and observing of clinical signs, exterior and gross lesions, and examining bacteria isolation and identification. Thirty-four(25.2%) of 135 control and vaccinated group fish were dead with serious anemia, abdominal extension, and hernia of intestine during 3 weeks post vaccination. We isolated Neoheterobothrium hirame from the buccal cavity and Edwardsiella tarda from kidney of dead and diseased fish. When infected fish with these agents were challenged with S. iniae SI-36 isolates, the cumulative mortality of control and vaccinated group were 86.7, and 46.7%, respectively. However, significant differences(p<0.05) were observed on cumulative mortality between control(20.0%) and vaccinated group(95.0%) at second trials with 40 healthy, and relative percent survival(RPS) was 78.0%. We confirmed that the efficacy of $\beta$-hemolytic S. iniae vaccine on olive flounder were impacted by health condition such as bacterial and parasitic diseases.

• 생명과학회지
• /
• 제32권5호
• /
• pp.375-390
• /
• 2022

인수공통 호흡기바이러스인 인플루엔자바이러스 감염으로 인해 공중보건과 가축산업에 심각한 피해가 지속적으로 발생하고 있다. 인플루엔자 백신 접종을 통해 항원형이 일치하는 바이러스 감염에 대해 우수한 방어면역을 제공하고 있으나, 효과적인 바이러스 감염 제어에는 여전히 큰 공백이 존재하고 있다. 다양한 항원형을 갖는 바이러스에 동시방어가 가능한 범용인플루엔자백신 개발과 함께 바이러스 치료효과를 제공하는 항바이러스제의 개발도 중요한 접근법으로 고려되고 있다. 현재 널리 사용되고 있는 인플루엔자 항바이러스제의 불완전한 치료효과와 내성바이러스의 출현 등의 문제들로 인해 식물 유래 천연물의 항바이러스 활성에 대한 관심이 증가하고 있다. 특히, 현재 진행 중인 코로나-19 팬데믹은 범용적인 항바이러스 활성을 갖는 안전하고 효과적인 항바이러스제 개발의 필요성을 뚜렷이 보여준다. 본 리뷰는 현재까지 보고된 천연물의 항인플루엔자바이러스 활성을 요약하였다. 또한, 항바이러스 활성을 갖는 천연물의 바이러스 사멸활성과 면역증강활성을 이용하는 신규 백신개발과 면역증강제 개발 가능성에 대해서도 분석하였다.

• Asian-Australasian Journal of Animal Sciences
• /
• 제22권4호
• /
• pp.465-470
• /
• 2009

The chicken Mx gene has been regarded as a candidate gene for resistance to avian influenza virus (AIV). In this study, three groups of chickens with homozygotes (AA, GG) and heterozygotes (AG) of the resistant (A) and susceptible alleles (G) to AIV of the Mx gene were constructed from a line of dwarf egg-type chickens. These chickens were not examined for their resistant activities to AIV because the differential resistance had only been detected in vitro. The birds of the three groups were vaccinated with inactivated H5N2 AIV vaccine and the level of hemagglutination inhibition (HI) antibody to AIV was detected. The association between disease resistant activity to AIV and antibody response to AIV vaccination in the three groups was analyzed. The chickens with homozygous resistant allele A showed the lowest antibody levels, whereas the heterozygous chickens (AG) presented the highest antibody level after the boosting vaccination, which indicates that the efficiency of artificial selection on the resistant allele of Mx gene will be compromised since the homozygotes of the allele presented the weakest antibody response to the corresponding vaccine.

• Toxicological Research
• /
• 제17권3호
• /
• pp.235-239
• /
• 2001

CJ-50005 is an inactivated whole virus vaccine derived from hepatitis A virus (HM175) grown in human MRC-5 diploid fibroblasts cell culture. In order to evaluate the mutagenic potential of CJ-50005, : 3 sets of mutagenicity tests were performed. In the reverse mutation test wing Salmonella typhimurium TA1535, TA1 537, TA98, TA100 and TA102, CJ-50005 did not increase the number of revertants at any concentration tested in this study (2.8, 1.4, 0.7, 0.35 and 0.175 $\mu\textrm{g}$/plate). CJ-50005, at concentration of 2.8, 1.4 and 0.7 $\mu\textrm{g}$/ml, did not increase the number of cells having structural or numerical chromosome aberration in cytogenic test using Chinese Hamster Lung cells. In mouse micronucleus test, no significant increase in the occurrence of micronucleated polychromatic erythrocytes was observed in ICR male and female mice intraperitoneally administered with CJ-50005 at the doses of 25, 12.5 and 6.25 $\mu\textrm{g}$/kg. These results indicate that CJ-50005 has no mutagenic potential in these in vitro and in vivo system.

• 대한미생물학회지
• /
• 제8권1호
• /
• pp.37-42
• /
• 1973

For the preparation of non-infective vaccine against typhoid fever, the authors had carried out an investigation on the possibilities of using $^{60}Co\;{\gamma}$-ray irradiation for the inactivation of Salmonella typhi Ty 2. The following results were obtained. 1) Chicks shortly after hatching were higher susceptible than mice to intracerebral injection with S. typhi. 2) In safety test on experimental animal, $^{60}Co\;{\gamma}$-ray irradiated vaccines demonstrated no clinical symptom while the phenol treated vaccines revealed several cases of narcosis by intraperitoneal injection in chicks. 3) The rabbit antisera immunized with $^{60}Co\;{\gamma}$-ray irradiated and phenol treated vaccine revealed almost same agglutinin titers to each other. 4) In potency test in chicks, there was no significance in the protective capacity between $^{60}Co\;{\gamma}$-ray irradiated and phenol treated vaccines.